Abstract: An angiotensin converting enzyme inhibitor containing Gly-Lys-Glu-Ile-Ile-Val-Lys-Ala-Glu-Arg (SEQ ID No: 1) Gly-Lys-Met-Val-Lys-Val-Val-Ser-Trp-Tyr (SEQ ID No: 2) or Ala-Tyr-Ile-Ala-Ser-Lys-Gly-Leu (SEQ ID No: 3) as an active component.

Abstract: New bicyclic compounds, inclusive of salts thereof, of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represents hydrogen, hydroxyl or lower alkoxy, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is hydrogen, lower alkyl, amino-lower-alkyl or acylamino-lower-alkyl, R.sup.5 is hydrogen, lower alkyl or aralkyl which may be substituted, R.sup.6 is hydroxyl, lower alkoxy, amino or lower alkylamino, and m and n each means 1 or 2, have inhibitory activities of angiotensin converting enzyme and bradykinin decomposing enzyme, and are useful as antihypertensive agents.

Abstract: The invention provides synthetic peptides which are extremely potent in stimulating the release of pituitary GH in animals, including humans and also resist enzymatic degradation in the body. The peptides have the sequence: (B)R.sub.1 -R.sub.2 -R.sub.3 -Ala-(Q.sub.1)R.sub.5 -Phe-Thr-R.sub.8 -Ser(Q.sub.2)R.sub.10 -Arg-R.sub.12 -(Q.sub.3)R.sub.13 -Leu-R.sub.15 -Gln-(Q.sub.4)Leu-R.sub.18 -(Q.sub.5)Ala-Arg-R.sub.21 -(Q.sub.6)R.sub.22 -(Q.sub.7)Leu-R.sub.24 -R.sub.25 -(Q.sub.8)R.sub.26 -(Q.sub.9)R.sub.27 -R.sub.28 -Arg-Gln-Gln-Gly-Glu-R.sub.34 -Asn-Gln-Glu-R.sub.38 -R.sub.39 -R.sub.40 -Arg-R.sub.42 -R.sub.43 -R.sub.44 wherein R.sub.1 is Tyr, D-Tyr, Met, Phe, D-Phe, pCl-Phe, Leu, His or D-His; B is H, C.sup.a Me, N.sup.a Me, desamino, Ac or For; R.sub.2 is Ala, D-Ala, NMA or D-NMA; R.sub.3 is Asp or D-Asp; R.sub.5 is Ile or Leu; R.sub.8 is Ser, Asn, Lys, Arg, Asp or Glu; R.sub.10 is Tyr, D-Tyr or Phe; R.sub.12 is Arg or Lys; R.sub.13 is Ile, Val, Leu or Ala; R.sub.15 is Gly or Ala; R.sub.18 is Ser or Tyr; R.sub.

Abstract: A method is provided for imhibiting loss of cognitive functon, including memory, which may or may not be associated with Alzheimer's disease, by administering an ACE inhibitor, such as captopril, fosinopril, zofenopril or ceranapril in combination with a drug that acts as serotonin receptors such as zacopride, over a prolonged period of treatment.

Abstract: The invention relates to the compounds of general formula (I): ##STR1## in which: A represents, with the carbon and nitrogen atoms to which it is linked, a cycloamide group,B represents, with the carbon and nitrogen atoms to which it is linked, a saturated polycyclic structure,R represents a hydrogen atom, alower alkyl group or a substituted or unsubstituted 4-imidazolylmethyl group,their diastereoisomers, enantiomers and epimers, as well as their addition salts with a pharmaceutically acceptable acid.Medicinal products.

Abstract: Glidobactin PF-1 of the formula ##STR1## having antitumor activity is prepared by cultivation of Polyangium brachysporum in a nutient medium containing a suitable fatty acid ester, such linolenate, together with other assimilable sources of carbon and nitrogen.

Abstract: Compounds of the formula I ##STR1## in which X denotes a hydrogen atom, a group which irreversibly masks the terminal amino group, or a protecting group which is conventional in peptide chemistry, such as, for example, Boc-, Z- or Fmoc-,A and B may be identical or different and denote an alipha-, beta- or gamma-amino acid which comprises 2 to 15 carbon atoms and up to 4 nitrogen atoms, 2 sulfur atoms and 6 oxygen atoms and whose side chain may be substituted, and B, if appropriate, denotes a dipeptide formed from these amino acids,C denotes arginine, lysine, tryrosine, phenylalanine or tryptophane, and their homologs,R.sub.1 and R.sub.2 are identical or different and denote a hydrogen atom or an alkyl radical having up to 4 carbon atoms,R.sub.3 to R.sub.8 are identical or different and denote hydrogen, an alkyl radical, an alkoxy radical or a hydrogen radical,Y denotes oxygen, andAn.sup.- denotes an anion,and their water-soluble salts, and a process for their preparation are described.

Abstract: A muscle relaxant and analgesic composition having at least five percent and preferably ten percent oil of Melaleuca spp. therein. The composition also contains other aromatic oils, such as camphor, menthol and methyl salicylate, a thickening agent, a preservative, and a carrier. The composition provides relief for sore muscles or joints when applied topically to the affected area. The Melaleuca oil preferably contains at least thirty percent terpinen-4-ol and less than fifteen percent 1,8-cineole.

Abstract: A nonlinear optical material obtained by blending 50-99% by weigth of a polypeptide and 1-50% by weight of a compound exerting a nonlinear optical response has a very large nonlinear optical constant, exterts a high and stable SHG activity and easily undergoes phase matching.

Abstract: The present invention relates to physiologically active peptides and more particularly, to novel peptides having a specific amino acid sequence which possess a macrophage chemotactic activity.

Abstract: A novel arthropodicidally-active composition-of-matter is disclosed. Such comprises an aqueous lower alkanol solvent, a toxicant contained within the solvent, and an effective amount of an emulsifier, also contained within the solvent, for forming a foam matrix of predetermined stability. Also disclosed are methods for producing such a composition-of-matter.

Abstract: A synthetic peptide of the human malaria Plasmodium vivax, containing at st one repeat of a synthetic peptide having the amino acid sequence Ala-Gly-Asp-Arg (AGDR) which is a protective epitope found on the circumsporozoite (CS) protein of the sporozoites of the human maleria Plasmodium vivax. When a monoclonal antibody specific for this four amino acid sequence binds to the CS protein of the P. vivax sporozoite in vivo, infection is prevented. Also described are pharmaceutical formulations of these peptides.

Abstract: In the esterification of glutathione with alcohol in the presence of acid catalyst, neutral glutathione monoester is isolated in high yields without the intermedite isolation of ester acid salt by treating the reaction mixture with base anion exchange resin (basic form) to neutralize the acid and bind the resulting acid anion and unesterified glutatione. Dehydrating agent is used to drive the reaction toward esterification. In the production of glutathione monester acid salts a soluble dehydrating agent is advantageously used.

Abstract: The present invention relates to the use of peptide hormone analogues as inhibitors of their respective naturally occurring peptide hormone. The structure of the peptide hormone analogues is exemplified by parathyroid hormone (PTH), wherein Lys.sup.13 is substituted to increase the biological activity of the PTH analogues. Thus, there are disclosed peptides having the formulae:PTH(7-34)NH.sub.2 ;[Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;[D-Trp.sup.12, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;[Nle.sup.8,18, D-Trp.sup.12, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;[Nle.sup.8,18, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ;desamino[Nle.sup.8,18, D-Trp.sup.12, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ; and,desamino[Nle.sup.8,18, D-Trp.sup.12, Tyr.sup.34 ]PTH(8-34)NH.sub.2wherein Lys.sup.13 is modified in the epsilon-amino acid group by N,N-diisobutyl or 3-phenylpropanoyl.

Abstract: Peptides are disclosed which inhibit the immune system. The peptides are selected from the group consisting of:Arg-Lys(Chc)-Asp-ValArg-Lys(Chc)-AspArg-Sar-Asp-ValArg-Sar-AspOrn-Lys-Asp-ValOrn-Lys-AspArg-Lys-Aad-ValArg-Lys-Aad[Arg-Lys-Asp-NH-CH.sub.2 -].sub.2 ##STR1##Lys-Ser-Lys-LeuSer-Lys-LeuSer-Ser-Ser-ThrLys-Glu-ThrLys-Thr-Glu-ThrPro-Lys-Leu-ThrLys-Lys-Thr-Glu andLys-His-Leu-NH.sub.2,and pharmaceutically acceptable acid addition salts thereof.

Abstract: Neutral lipids are provided characterized by binding to phorboid and ingenoid receptors. These lipids are found in a wide variety of cellular sources as well as milk and may be isolated by specific extraction and chromatographic procedures. Depending upon the source, the glycerides may be mono- or di-glycerides, wherein the total number of carbon atoms of the fatty acis is in the range of 18 to 26, so that the monoglyceride has a fatty acid of at least 18 carbon atoms, while the di-glyceride has a fatty acid of at least 14 carbon atoms. The long chain fatty acids have at least one site of olefinic unsaturation.

Abstract: The invention relates to the use of aids of the general formula ##STR1## in which B denotes a basic amino acid, A/B denotes an acidic or basic amino acid, X denotes a neutral and hydrophilic amino acid, L denotes a lipophilic neutral amino acid, and R denotes hydrogen or an acyl radical, or the physiologically tolerated salts thereof, for promoting the absorption of peptides and proteins on administration onto the mocosa, as well as to pharmaceutical compositions which contain a pharmacologically effective amount of one or more peptides or proteins as well as an aid of the abovementioned formula.

Abstract: The invention relates to peptides of the formula ##STR1## in which X is absent or is hydrogen or acyl; A is Pgl, de-hydro-Pro, Pro, D-Thi or D-Pgl or represents optionally substituted D-Nal(2), D-Phe or D-Trp; B is His or optionally substituted D-Phe; C is Trp, D-Thi, D-Pal(3) or optionally substituted D-Trp; D is Tyr, Arg of His; E is D-Ser(R.sup.1), .beta.-Asn, .beta.-Asp-OMe, D-Thi or --NH--CH(CH.sub.2 R.sup.2)--CO--; F is Ser(R.sup.1), Leu, Trp or Phe; G is Gly-NH.sub.2, Aza-Gly-NH.sub.2, D-Ala-NH.sub.2 or NH-alkyl; R.sup.1 is glycosyl and R.sup.2 is hydrogen, acyl, aryl or heteroaryl.The invention also relates to methods for the preparation of these peptides, agents containing them and their use.

Abstract: New analogues of thymopentin (TP5) and of its tetrapeptide fragment (TP5.sup.1-4) containing two non-contiguous retro-inverted bonds in the peptide chain are described.The new compounds, of general formula (I) ##STR1## where R is hydrogen or an acyl radical, andR.sup.1 is an --OR.sup.2 group or an ##STR2## group where R.sup.2 is a hydrogen atom or a hydrocarbon radical, and R.sup.3 is a hydrogen atom or a hydroxyl group,and the corresponding pharmaceutically acceptable salts of acid or basic addition, possess immunomodulating activity.

Abstract: A method of removing heavy metals from aqueous solution, a composition of matter used in effecting said removal, and apparatus used in effecting said removal. One or more of the polypeptides, poly (.gamma.-glutamylcysteinyl)glycines, is immobilized on an inert material in particulate form. Upon contact with an aqueous solution containing heavy metals, the polypeptides sequester the metals, removing them from the solution. There is selectivity of poly (.gamma.-glutamylcysteinyl)glycines having a particular number of monomer repeat units for particular metals. The polypeptides are easily regenerated by contact with a small amount of an organic acid, so that they can be used again to remove heavy metals from solution. This also results in the removal of the metals from the column in a concentrated form.